ARCHIVES

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

This article is from The Cancer Letter archive.

Vol. 23 No. 32 | August 15, 1997

Download PDF Visit The Full Archive

Related Articles

Arzerra Given Accelerated Approval For Leukemia

October 30, 2009

Correction: Appropriations Reports Included Language of Minorities and Underserved

October 15, 1999

Clinical Sciences Director Liu To Head Singapore Program.

January 12, 2001

COG’s Peter Adamson Has A Conversation With The Cancer Letter

March 15, 2013

NCI Clarifies Policy On Small, Short-Term Research Grants

July 5, 1996

NCI Director May Alert Cancer Panel to Freeze On GS-13 Promotion

November 4, 1994